Author's Reply to Comments to: Clinical Experience of Switching Anti-VEGF Therapy from Ranimizumab to Aflibercept in Age-Related Choroidal Neovascularization
Restricted accessResearch articleFirst published online May, 2017
Author's Reply to Comments to: Clinical Experience of Switching Anti-VEGF Therapy from Ranimizumab to Aflibercept in Age-Related Choroidal Neovascularization
Van LanckerLet al.Clinical experience of switching anti-VEGF therapy from ranibizumab to aflibercept in age-related choroidal neovascularization.Eur J Ophthalmol2016Oct3 doi: 10.5301/ejo.5000861. [Epub ahead of print].
